Gene Therapy Market Quantitative Analysis, Current and Future Trends

According to a P&S Intelligence report, the global gene therapy market attained a revenue of $3,407.5 million in 2019 and is predicted to exhibit a 31.1% CAGR during the forecast period (2020–2030). The market is being driven by the rising research & development (R&D), increasing number of clinical trials that have shown positive results, and growing prevalence of chronic diseases. In terms of vector type, the market is divided into non-viral, viral, and other.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/gene-therapy-market/report-sample

Out of these, the viral division is expected to account for the largest share of the gene therapy market by 2030, which is due to the fact that vectors show higher genomic incorporation levels and expression during clinical trials. In addition to this, these vectors are more efficient as compared to non-viral vectors. On the basis of type, the market is categorized into ex vivo and in vivo, between which, the in vivo category held the larger revenue share of the market during the historical period (2014–2019).

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=gene-therapy-market

The major companies in the gene therapy market are engaging in partnerships and collaborations for their expansion. For example, Lonza Group Ltd. partnered with DiNAQOR AG in November 2019 for advancing the latter companies pre-clinical program revolving around the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies. The terms of the partnership state that Lonza will provide clinical, pre-clinical, and commercial production support for a gene therapy program initiated by DiNAQOR AG, DiNA-001. 

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Aug 21st 2020 03:55. Viewed 269 times.

Share on APSense

Comments